PET/CT in diagnosis of dementia
Identifieur interne : 002173 ( Main/Corpus ); précédent : 002172; suivant : 002174PET/CT in diagnosis of dementia
Auteurs : Valentina Berti ; Alberto Pupi ; Lisa MosconiSource :
- Annals of the New York Academy of SciencesPET/CT Applications in Non‐neoplastic Conditions [ 0077-8923 ] ; 2011-06.
English descriptors
- KwdEn :
Abstract
Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.
Url:
DOI: 10.1111/j.1749-6632.2011.06015.x
Links to Exploration step
ISTEX:C362509DC7D31449EA16CE914E02333CD5BFAC81Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">PET/CT in diagnosis of dementia</title><author><name sortKey="Berti, Valentina" sort="Berti, Valentina" uniqKey="Berti V" first="Valentina" last="Berti">Valentina Berti</name><affiliation><mods:affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</mods:affiliation></affiliation></author><author><name sortKey="Pupi, Alberto" sort="Pupi, Alberto" uniqKey="Pupi A" first="Alberto" last="Pupi">Alberto Pupi</name><affiliation><mods:affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</mods:affiliation></affiliation></author><author><name sortKey="Mosconi, Lisa" sort="Mosconi, Lisa" uniqKey="Mosconi L" first="Lisa" last="Mosconi">Lisa Mosconi</name><affiliation><mods:affiliation>Center for Brain Health, New York University School of Medicine, New York, New York</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C362509DC7D31449EA16CE914E02333CD5BFAC81</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1749-6632.2011.06015.x</idno><idno type="url">https://api.istex.fr/document/C362509DC7D31449EA16CE914E02333CD5BFAC81/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002173</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">PET/CT in diagnosis of dementia</title><author><name sortKey="Berti, Valentina" sort="Berti, Valentina" uniqKey="Berti V" first="Valentina" last="Berti">Valentina Berti</name><affiliation><mods:affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</mods:affiliation></affiliation></author><author><name sortKey="Pupi, Alberto" sort="Pupi, Alberto" uniqKey="Pupi A" first="Alberto" last="Pupi">Alberto Pupi</name><affiliation><mods:affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</mods:affiliation></affiliation></author><author><name sortKey="Mosconi, Lisa" sort="Mosconi, Lisa" uniqKey="Mosconi L" first="Lisa" last="Mosconi">Lisa Mosconi</name><affiliation><mods:affiliation>Center for Brain Health, New York University School of Medicine, New York, New York</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the New York Academy of SciencesPET/CT Applications in Non‐neoplastic Conditions</title><idno type="ISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">1228</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="81">81</biblScope><biblScope unit="page" to="92">92</biblScope></imprint><idno type="ISSN">0077-8923</idno></series><idno type="istex">C362509DC7D31449EA16CE914E02333CD5BFAC81</idno><idno type="DOI">10.1111/j.1749-6632.2011.06015.x</idno><idno type="ArticleID">NYAS6015</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0077-8923</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer’s disease</term><term>PET/CT</term><term>dementia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Valentina Berti</name><affiliations><json:string>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</json:string></affiliations></json:item><json:item><name>Alberto Pupi</name><affiliations><json:string>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</json:string></affiliations></json:item><json:item><name>Lisa Mosconi</name><affiliations><json:string>Center for Brain Health, New York University School of Medicine, New York, New York</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>PET/CT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Alzheimer’s disease</value></json:item></subject><articleId><json:string>NYAS6015</json:string></articleId><language><json:string>eng</json:string></language><abstract>Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.</abstract><qualityIndicators><score>7.072</score><pdfVersion>1.4</pdfVersion><pdfPageSize>504 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>988</abstractCharCount><pdfWordCount>6194</pdfWordCount><pdfCharCount>41488</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>131</abstractWordCount></qualityIndicators><title>PET/CT in diagnosis of dementia</title><genre><json:string>article</json:string></genre><host><volume>1228</volume><publisherId><json:string>NYAS</json:string></publisherId><pages><total>12</total><last>92</last><first>81</first></pages><issn><json:string>0077-8923</json:string></issn><issue>1</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1749-6632</json:string></eissn><title>Annals of the New York Academy of SciencesPET/CT Applications in Non‐neoplastic Conditions</title><doi><json:string>10.1111/(ISSN)1749-6632</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1749-6632.2011.06015.x</json:string></doi><id>C362509DC7D31449EA16CE914E02333CD5BFAC81</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C362509DC7D31449EA16CE914E02333CD5BFAC81/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C362509DC7D31449EA16CE914E02333CD5BFAC81/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C362509DC7D31449EA16CE914E02333CD5BFAC81/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">PET/CT in diagnosis of dementia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">PET/CT in diagnosis of dementia</title><author><persName><forename type="first">Valentina</forename><surname>Berti</surname></persName><affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</affiliation></author><author><persName><forename type="first">Alberto</forename><surname>Pupi</surname></persName><affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</affiliation></author><author><persName><forename type="first">Lisa</forename><surname>Mosconi</surname></persName><affiliation>Center for Brain Health, New York University School of Medicine, New York, New York</affiliation></author></analytic><monogr><title level="j">Annals of the New York Academy of SciencesPET/CT Applications in Non‐neoplastic Conditions</title><idno type="pISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><idno type="DOI">10.1111/(ISSN)1749-6632</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-06"></date><biblScope unit="volume">1228</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="81">81</biblScope><biblScope unit="page" to="92">92</biblScope></imprint></monogr><idno type="istex">C362509DC7D31449EA16CE914E02333CD5BFAC81</idno><idno type="DOI">10.1111/j.1749-6632.2011.06015.x</idno><idno type="ArticleID">NYAS6015</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>PET/CT</term></item><item><term>dementia</term></item><item><term>Alzheimer’s disease</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C362509DC7D31449EA16CE914E02333CD5BFAC81/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Inc</publisherName><publisherLoc>Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1749-6632</doi><issn type="print">0077-8923</issn><issn type="electronic">1749-6632</issn><idGroup><id type="product" value="NYAS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ANNALS OF NEW YORK ACADEMY SCIENCES">Annals of the New York Academy of Sciences</title></titleGroup></publicationMeta><publicationMeta level="part" position="12281"><doi origin="wiley">10.1111/nyas.2011.1228.issue-1</doi><titleGroup><title type="main">PET/CT Applications in Non‐neoplastic Conditions</title></titleGroup><numberingGroup><numbering type="journalVolume" number="12281">1228</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2011-06">June 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="9" status="forIssue"><doi origin="wiley">10.1111/j.1749-6632.2011.06015.x</doi><idGroup><id type="unit" value="NYAS6015"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title></titleGroup><copyright>© 2011 New York Academy of Sciences.</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.10 mode:FullText" date="2011-09-22"></event><event type="publishedOnlineFinalForm" date="2011-06-30"></event><event type="firstOnline" date="2011-06-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-19"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="81">81</numbering><numbering type="pageLast" number="92">92</numbering></numberingGroup><correspondenceTo>Valentina Berti, Department of Clinical Pathophysiology, Nuclear Medicine Unit, viale Morgagni 85, Florence 50134, Italy. <email>valentina.berti@unifi.it</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:NYAS.NYAS6015.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="2"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="89"></count><count type="linksCrossRef" number="125"></count></countGroup><titleGroup><title type="main">PET/CT in diagnosis of dementia</title><title type="shortAuthors">Berti <i>et al.</i></title><title type="short">PET/CT in diagnosis of dementia</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Valentina</givenNames><familyName>Berti</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Alberto</givenNames><familyName>Pupi</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><givenNames>Lisa</givenNames><familyName>Mosconi</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="IT"><unparsedAffiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="US"><unparsedAffiliation>Center for Brain Health, New York University School of Medicine, New York, New York</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">PET/CT</keyword><keyword xml:id="k2">dementia</keyword><keyword xml:id="k3">Alzheimer’s disease</keyword></keywordGroup><supportingInformation><p><b>Figure S1.</b> [<sup>18</sup>F]FDG PET in different forms of Lewy body disease (LBD), showing two representative cases with dementia with Lewy bodies (DLB, left) and Parkinson's disease with dementia (PDD, right).</p><supportingInfoItem><mediaResource alt="supporting info item" href="urn-x:wiley:00778923:media:nyas6015:NYAS_6015_sm_FigureS1"></mediaResource><caption>Supporting info item</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><p>Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>PET/CT in diagnosis of dementia</title></titleInfo><titleInfo type="abbreviated"><title>PET/CT in diagnosis of dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>PET/CT in diagnosis of dementia</title></titleInfo><name type="personal"><namePart type="given">Valentina</namePart><namePart type="family">Berti</namePart><affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alberto</namePart><namePart type="family">Pupi</namePart><affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lisa</namePart><namePart type="family">Mosconi</namePart><affiliation>Center for Brain Health, New York University School of Medicine, New York, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Inc</publisher><place><placeTerm type="text">Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2011-06</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">2</extent><extent unit="references">89</extent></physicalDescription><abstract lang="en">Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau‐proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.</abstract><subject lang="en"><genre>Keywords</genre><topic>PET/CT</topic><topic>dementia</topic><topic>Alzheimer’s disease</topic></subject><relatedItem type="host"><titleInfo><title>Annals of the New York Academy of SciencesPET/CT Applications in Non‐neoplastic Conditions</title></titleInfo><genre type="Journal">journal</genre><note type="content"> Figure S1. [18F]FDG PET in different forms of Lewy body disease (LBD), showing two representative cases with dementia with Lewy bodies (DLB, left) and Parkinson's disease with dementia (PDD, right).Supporting Info Item: Supporting info item - </note><identifier type="ISSN">0077-8923</identifier><identifier type="eISSN">1749-6632</identifier><identifier type="DOI">10.1111/(ISSN)1749-6632</identifier><identifier type="PublisherID">NYAS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>1228</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>81</start><end>92</end><total>12</total></extent></part></relatedItem><identifier type="istex">C362509DC7D31449EA16CE914E02333CD5BFAC81</identifier><identifier type="DOI">10.1111/j.1749-6632.2011.06015.x</identifier><identifier type="ArticleID">NYAS6015</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011 New York Academy of Sciences.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Inc</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002173 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002173 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:C362509DC7D31449EA16CE914E02333CD5BFAC81
|texte= PET/CT in diagnosis of dementia
}}
| This area was generated with Dilib version V0.6.23. |  |